NDAORALTABLET, EFFERVESCENT
Approved
Mar 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
7
Data completeness
7/8 — Comprehensive
BINOSTO (alendronate sodium) by Radius Health is action. Approved for osteoporosis, osteopenia, glucocorticoid-induced osteoporosis. First approved in 2012.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BINOSTO is an oral effervescent tablet formulation of alendronate sodium, a bisphosphonate approved in 2012 for osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, and other bone disorders. It works by inhibiting osteoclast activity and reducing bone turnover, allowing bone formation to exceed resorption and progressively increase bone mass. The drug localizes preferentially to sites of active bone resorption and must be continuously administered to suppress osteoclasts on newly formed resorption surfaces.
$0.539MPart D
Peak5.6 years to LOEProduct is in peak lifecycle phase with minimal Part D spending and claims, indicating mature market penetration with stable but limited growth potential.
Mechanism of Action
action. At the cellular level, alendronate shows preferential localization to sites of bone resorption, specifically under osteoclasts. The osteoclasts adhere normally to the bone surface but lack the ruffled border that is indicative of active resorption. Alendronate does not interfere with…
Indications (3)
Worked on BINOSTO at Radius Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.